To investigate the safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with cirrhosis and portal hypertension.

The data of 123 patients with hepatocellular carcinoma complicated with cirrhosis portal hypertension from July 2016 to June 2021 were retrospectively analyzed, and they were divided into TACE group and combination group according to different treatment plans. 60 patients in the TACE group received simple hepatic arterial chemoembolization (TACE) treatment, and 63 patients in the combination group, respectively. He received transjugular intrahepatic portal shunt (TIPS) combined with TACE. SPSS 23.0 statistical software was used to analyze the data. The portal vein and other measurement data were expressed as () and independent sample t test was used. The complications were counted by χ² test. The survival rate was measured by Log-Rank method. P<0.05 was considered statistically significant.

The total response rate of patients in combination group (82.5%) was slightly higher than that in TACE group (76.7%) (P>0.05). Postoperative portal vein pressure and portal vein diameter in combination group were lower than those in TACE group (P<0.05). There was no significant difference in the total incidence of complications between the combined group (22.2%) and the TACE group (21.7%) (P > 0.05). The 1 - and 2-year survival rates in combination group were higher than those in TACE group (P<0.05).

TIPS combined with TACE in the treatment of portal hypertension in liver cancer complicated with cirrhosis has definite clinical efficacy, can reduce portal pressure, improve postoperative survival rate of patients, and does not increase the risk of complications.